Skip to main content

2.

Primary and triage screening performance of physician- and self-collected careHPV at ≥1.0 RLU/CO for CIN3+ detection among 2,337 women, compared to VIA and cytology primary screening, and physician-HC2 triage strategies

Primary Screening Triage strategy CIN3+ (N=23) % (95% CI) Colposcopy per CIN3+ (N)
Sensitivity Specificity PPV NPV Youden’s index
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; VIA, visual inspection with acetic acid; HC2, Hybrid Capture 2; ASC-H+, atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesions or worse; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; ASC-US+, atypical squamous cells of undetermined significance or worse.
Physician- careHPV ≥1.0 RLU/CO None 20 87.0
(67.9–95.5)
86.7
(85.2–88.0)
6.1
(4.0–9.2)
99.9
(99.6–99.9)
73.6
(71.8–75.4)
16.4
ASC-US+ 19 82.6
(62.9–93.0)
93.5
(92.4–94.5)
11.2
(7.3–16.9)
99.8
(99.5–99.9)
76.1
(74.4–77.8)
8.9
VIA 12 52.2
(33.0–70.8)
98.8
(98.3–99.2)
30.0
(18.1–45.4)
99.5
(99.1–99.7)
51.0
(49.0–53.0)
3.3
Self-careHPV ≥1.0 RLU/CO None 18 78.3
(58.1–90.3)
87.1
(85.7–88.4)
5.7
(3.6–8.8)
99.8
(99.4–99.9)
65.3
(63.4–67.2)
17.6
ASC-US+ 16 69.6
(49.1–84.4)
95.2
(94.3–96.0)
12.6
(7.9–19.5)
99.7
(99.3–99.8)
64.8
(62.9–66.7)
7.9
VIA 10 43.5
(25.6–63.2)
98.9
(98.4–99.2)
27.8
(15.8–44.0)
99.4
(99.0–99.7)
42.4
(40.4–44.4)
3.6
Physician- HC2 ≥1.0 RLU/CO None 22 95.7
(79.0–99.2)
84.4
(82.8–85.8)
5.7
(3.8–8.5)
99.9
(99.7–100)
80.0
(78.4–81.6)
17.5
ASC-US+ 21 91.3
(73.2–97.6)
92.7
(91.5–93.6)
11.0
(7.3–16.2)
99.9
(99.7–100)
84.0
(82.5–85.5)
9.1
VIA 13 56.5
(36.8–74.4)
98.5
(97.9–98.9)
27.1
(16.6–41.0)
99.6
(99.2–99.8)
55.0
(53.0–57.0)
3.7
Cytology (ASC-H+) None 20 87.0
(67.9–95.5)
95.4
(94.4–96.2)
15.7
(10.4–23.1)
99.9
(99.6–100)
82.4
(80.9–83.9)
6.4
VIA None 13 56.5
(36.8–74.4)
94.5
(93.5–95.4)
9.3
(5.5–15.2)
99.5
(99.2–99.8)
51.0
(49.0–53.0)
10.8